Effects of mono- and dual blockade of the renin-angiotensin system on markers of cardiovascular status in hypertensive patients with mild and moderate renal failure

Kidney and Blood Pressure Research

Volumn 34, Issue 3, 2011, Pages 150-157

  Nagy, Gábor ^a,b   Szijártó, István A ^a   Gaszner, Balázs ^b   Lányi, Éva ^b   Markó, Lajos ^a   Mérei, Ákos ^a   Molnár, Gergo A ^a   Németh, Kinga ^b   Betlehem, József ^b   Wittmann, István ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Brain natriuretic peptide; Endogenous ouabain; Immuno unreactive urinary albumin; Renal failure; Renin angiotensin system blockade; Subclinical organ damage

Indexed keywords

ADRENALIN; ALANINE AMINOTRANSFERASE; ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CALCIUM; CHLORIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORADRENALIN; OUABAIN; POTASSIUM; SODIUM; TRIACYLGLYCEROL;

ADRENALIN BLOOD LEVEL; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALBUMINURIA; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE MONITORING; CARDIOVASCULAR SYSTEM; CARDIOVASCULAR SYSTEM EXAMINATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFECT; ECHOCARDIOGRAPHY; ERYTHROCYTE COUNT; FEMALE; HEALTH STATUS; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LONG TERM CARE; MALE; MEAN ARTERIAL PRESSURE; NORADRENALIN BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM BLOOD LEVEL; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ALBUMINS; ARTERIES; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CATECHOLAMINES; CROSS-SECTIONAL STUDIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEPHROSCLEROSIS; OUABAIN; PEPTIDE FRAGMENTS; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES;

EID: 79952105335     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000324465     Document Type: Article

References (27)

1. Bell DS: Hypertension and diabetes: a toxic combination. Endocr Pract 2008; 14: 1031-1039.
2. Azizi M, Ménard J: Combined blockade of the renin-angiotensin system with angiotensin- converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004; 109: 2492-2499. (Pubitemid 38720545)
3. Weir MR: Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007; 29: 1803-1824. (Pubitemid 350214460)
4. Sengul AM, Altuntas Y, Kürklü A, Aydin L: Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract 2006; 71: 210-219. (Pubitemid 43112114)
5. Anan F, Takahashi N, Ooie T, Yufu K, Hara M, Nakagawa M, Yonemochi H, Saikawa T, Yoshimatsu H: Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol 2005; 61: 353-359. (Pubitemid 41569309)
6. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. (Pubitemid 351522739)
7. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET Investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
8. Bagrov AY, Shapiro JI. Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nat Clin Pract Nephrol 2008; 4: 378-392. (Pubitemid 351913708)
9. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P: N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616. (Pubitemid 40471791)
10. Orea-Tejeda A, Colín-Ramírez E, Hernández- Gilsoul T, Castillo-Martínez L, Abasta- Jiménez M, Asensio-Lafuente E, Narváez David R, Dorantes-García J: Microalbuminuria in systolic and diastolic chronic heart failure patients. Cardiol J 2008; 15: 143-149. (Pubitemid 351721975)
11. Polkinghorne KR, Su Q, Chadban SJ, Shaw JE, Zimmet PZ, Atkins RC: Population prevalence of albuminuria in the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study: immunonephelometry compared with high-performance liquid chromatography. Am J Kidney Dis 2006; 47: 604-613.
12. Jager A, Kostense PJ, Ruhé HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CD: Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: fiveyear follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 617-624. (Pubitemid 29135163)
13. Deckert T, Kofoed-Enevoldsen A, Nørgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T: Microalbuminuria. Implications for micro- and macro-vascular disease. Diabetes Care 1992; 15: 1181-1191.
14. Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A, Ruello N, Tomolillo C, Castello C, Grillo G, Sacchi G, Deferrari G: Prevalence and clinical correlates of microalbuminuria in essential hypertension. The MAGIC study. A Genoa investigation on complications. Hypertension 1997; 30: 1135-1143. (Pubitemid 27476170)
15. Osicka TM, Comper WD: Characterization of immunochemically nonreactive urinary albumin. Clin Chem 2004; 50: 2286-2291. (Pubitemid 39552163)
16. Clavant SP, Sastra SA, Osicka TM, Comper WD: The analysis of immuno-unreactive urinary albumin in healthy volunteers. Clin Biochem 2006; 39: 143-151. (Pubitemid 43255503)
17. Weir MR: Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007; 2: 581-590.
18. Vakkuri O, Arnason SS, Joensuu P, Jalonen J, Vuolteenaho O, Leppäluoto J: Radioiodinated tyrosyl-ouabain and measurement of a circulating ouabain-like compound. Clin Chem 2001; 47: 95-101. (Pubitemid 32064281)
19. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R: Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004; 6: 365-368. (Pubitemid 38253059)
20. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, Morehead A, Kitzman D, Oh J, Quinones M, Schiller NB, Stein JH, Weissman NJ, American Society of Echocardiography: American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 2004; 17: 1086-1119.
21. Niki K, Sugawara M, Chang D, Harada A, Okada T, Sakai R, Uchida K, Tanaka R, Mumford CE: A new noninvasive measurement system for wave intensity: evaluation of carotid arterial wave intensity and reproducibility. Heart Vessels 2002; 17: 12-21. (Pubitemid 35423059)
22. Okamoto S, Ikeda M, Morise T, Miyamori I, Takeda R: Elevated endogenous digitalislike substance in hypertensive diabetic patients with a family history of hypertension. J Endocrinol Invest 1991; 14: 357-360.
23. Skoumal R, Szokodi I, Aro J, Földes G, Göoz M, Seres L, Sármán B, Lakó-Futó Z, Papp L, Vuolteenaho O, Leppäluoto J, DeChâtel R, Ruskoaho H, Tóth M: Involvement of endogenous ouabain-like compound in cardiac hypertrophic process in vivo. Life Sci 2007; 80: 1303-1310.
24. Strong KJ, Osicka TM, Comper WD: Urinary- peptide excretion by patients with and volunteers without diabetes. J Lab Clin Med 2005; 145: 239-246. (Pubitemid 40719930)
25. Nakayama A, Sakatsume M, Kasama T, Kawara T, Gejyo F, Isobe M, Sato K, Shiba K: Molecular heterogeneity of urinary albumin in glomerulonephritis: comparison of cardiovascular disease with albuminuria. Clin Chim Acta 2009; 402: 94-101.
26. Gudehithlu KP, Pegoraro AA, Dunea G, Arruda JA, Singh AK: Degradation of albumin by the renal proximal tubule cells and the subsequent fate of its fragments. Kidney Int 2004; 65: 2113-2122. 27 Markó L, Molnár GA, Wagner Z, Böddi K, Koszegi T, Szabó Z, Matus Z, Szijá rtó I, Mérei A, Nagy G, Wittmann I: Measurement of the modification and interference rate of urinary albumin detected by size-exclusion HPLC. Physiol Meas 2009; 30: 1137-1150. (Pubitemid 38669997)
27. Markó L, Molnár GA, Wagner Z, Böddi K, Koszegi T, Szabó Z, Matus Z, Szijártó I, Mérei A, Nagy G, Wittmann I: Measurement of the modification and interference rate of urinary albumin detected by size-exclusion HPLC. Physiol Meas 2009; 30: 1137-1150